Document Detail

Metabonomics in preclinical drug development.
MedLine Citation:
PMID:  16863449     Owner:  NLM     Status:  MEDLINE    
Metabonomics has emerged as a key technology in preclinical drug discovery and development. The technology enables noninvasive systems assessment of untoward effects induced by candidate compounds characterising a broad spectrum of biological responses on an individual animal basis in a relatively rapid-throughput fashion, thus making it an ideal addition to early preclinical safety assessment. However, the implementation and interpretation of the technology and data it generates is not something that should be trivialised. Proper expertise in biological sciences, analytical sciences (nuclear magnetic resonance and/or mass spectrometry) and chemometrics should all be considered necessary prerequisites. If these factors are properly considered, the technology can add significant value as a tool for preclinical toxicologists.
Donald G Robertson; Michael D Reily; J David Baker
Related Documents :
24058519 - Development of novel (123)i-labeled pyridyl benzofuran derivatives for spect imaging of...
24350159 - Interpretation of computed tomography of the head: emergency physicians versus radiolog...
25085699 - Mri evaluation of the anterolateral ligament of the knee: assessment in routine 1.5-t s...
15043649 - Keeping it short: a comparison of methods for brief picture presentation.
24993639 - Dynamic ct perfusion imaging of the myocardium using a wide-detector scanner: a semiqua...
25084979 - Reliability analysis of visual ranking of coronary artery calcification on low-dose ct ...
23372439 - (18)f-flt-pet for response evaluation of mek inhibitor selumetinib (azd6244, arry-14288...
17192319 - Results of arthroscopic fixation of osteochondritis dissecans lesion of the knee with c...
15647829 - Gorham-stout disease--stabilization during bisphosphonate treatment.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on drug metabolism & toxicology     Volume:  1     ISSN:  1742-5255     ISO Abbreviation:  Expert Opin Drug Metab Toxicol     Publication Date:  2005 Oct 
Date Detail:
Created Date:  2006-07-25     Completed Date:  2006-08-29     Revised Date:  2009-11-16    
Medline Journal Info:
Nlm Unique ID:  101228422     Medline TA:  Expert Opin Drug Metab Toxicol     Country:  England    
Other Details:
Languages:  eng     Pagination:  363-76     Citation Subset:  IM    
Pfizer Global Research and Development, Department of World Wide Safety Sciences, 2800 Plymouth Rd, Ann Arbor, MI 48105, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Drug Evaluation, Preclinical / methods*
Metabolism / genetics*,  physiology*
Pharmaceutical Preparations / adverse effects
Research Design
Reg. No./Substance:
0/Pharmaceutical Preparations

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacodynamics of antimicrobials: treatment optimisation.
Next Document:  Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus...